{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058186","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.071415+00:00","generated_at":"2026-06-02T02:34:47.051292+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed","bullets":["Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.","Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.","BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.","First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058186","json":"https://secwatch.observer/filing/0000950170-24-058186.json","markdown":"https://secwatch.observer/filing/0000950170-24-058186.md","text":"https://secwatch.observer/filing/0000950170-24-058186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/0000950170-24-058186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/bold-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:34:47.051292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff409305d70e59fb0ec397b78e1057deeda85009","claim":"Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.","evidence_excerpt":"Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/0000950170-24-058186-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$15.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}